Refine
Has Fulltext
- yes (25)
Is part of the Bibliography
- yes (25)
Year of publication
Document Type
- Journal article (25)
Language
- English (25) (remove)
Keywords
- glioblastoma multiforme (6)
- glioblastoma (5)
- recurrence (5)
- astrocytoma (4)
- mRNA (3)
- protein (3)
- relapse (3)
- therapy (3)
- vestibular schwannoma (3)
- CNS disorders (2)
- MPS1 (2)
- Tumor Treating Fields (TTFields) (2)
- blood–brain barrier (2)
- brain (2)
- expression (2)
- glioma (2)
- low-grade glioma (2)
- mRNA expression (2)
- organoids (2)
- pathogenesis (2)
- temozolomide (2)
- 3D ex vivo models (1)
- 3D in vitro model (1)
- ADAM9 (1)
- Astrocytic tumor (1)
- Bevacizumab (1)
- Blood–brain barrier (1)
- CNS diseases (1)
- CX3CL1 (1)
- CXCL13 (1)
- CXCR4 (1)
- Expression (1)
- Glioblastom (1)
- Glioblastoma (1)
- Glioblastoma cell line (1)
- Glioblastoma multiforme (1)
- Glioblastomas (1)
- HERV-K (1)
- Human endogenous retrovirus (1)
- IDH (1)
- In vitro models (1)
- Irradiation (1)
- MGMT (1)
- MGMT promoter methylation (1)
- Merlin (1)
- Metalloproteinasen (1)
- Metastatic breast cancer (1)
- N-Myc down regulated gene 1 (1)
- NF2-related schwannomatosis (NF2) (1)
- PCDHGC3 (1)
- PCR analysis (1)
- PET/CT (1)
- Pentixafor (1)
- Short dsRNA oligonucleotides (1)
- Spinal dissemination (1)
- Strahlentherapie (1)
- TTFields (1)
- TTK (1)
- Temozolomide (1)
- Tumor-Treating Fields (TTFields) (1)
- WNT signaling (1)
- aging (1)
- anticancer activity (1)
- astrocytic tumor (1)
- behavior (1)
- blood-brain barrier (1)
- brain cancer (1)
- cancer stem cells (1)
- deafness (1)
- expression pattern (1)
- glioblastoma cell-lines (1)
- glioblastoma multiforme (GBM) (1)
- growth pattern (1)
- human brain microvascular endothelial cells (HBMVEC) (1)
- human cancer diseases (1)
- human cells (1)
- immunofuorescence double staining (1)
- in vitro model (1)
- integrin (1)
- knock down (1)
- liponeurocytoma (1)
- liquid biopsy (1)
- matrix metalloproteinase (1)
- mechanism of action (1)
- medulloblastoma (1)
- metastasis (1)
- metastasis associated in colorectal cancer 1 (MACC1) (1)
- metastasis-associated in colon cancer 1 (MACC1) (1)
- molecular imaging (1)
- molecular signature (1)
- multifocal growth (1)
- neurocytoma (1)
- non-small cell lung cancer (NSCLC) (1)
- organotypic hippocampal slice cultures (OHSC) (1)
- ovarian cancer (1)
- palladium (1)
- pancreatic cancer (1)
- platinum (1)
- primary cell culture (1)
- prognostic marker (1)
- protein and mRNA expression (1)
- radiotherapy (1)
- resistance (1)
- senescence (1)
- slice culture (1)
- suppressor (1)
- taxanes (1)
- therapy response (1)
- thiosemicarbazone (1)
- tumor slice cultures (1)
- tumormicroenvironment (1)
Institute
- Neurochirurgische Klinik und Poliklinik (23)
- Pathologisches Institut (14)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (5)
- Frauenklinik und Poliklinik (3)
- Neurologische Klinik und Poliklinik (2)
- Augenklinik und Poliklinik (1)
- Graduate School of Life Sciences (1)
- Institut für Anatomie und Zellbiologie (1)
- Institut für Anorganische Chemie (1)
- Kinderklinik und Poliklinik (1)
Progressive deterioration of the central nervous system (CNS) is commonly associated with aging. An important component of the neurovasculature is the blood-brain barrier (BBB), majorly made up of endothelial cells joined together by intercellular junctions. The relationship between senescence and changes in the BBB has not yet been thoroughly explored. Moreover, the lack of in vitro models for the study of the mechanisms involved in those changes impede further and more in-depth investigations in the field. For this reason, we herein present an in vitro model of the senescent BBB and an initial attempt to identify senescence-associated alterations within.
Despite the availability of numerous therapeutic substances that could potentially target CNS disorders, an inability of these agents to cross the restrictive blood–brain barrier (BBB) limits their clinical utility. Novel strategies to overcome the BBB are therefore needed to improve drug delivery. We report, for the first time, how Tumor Treating Fields (TTFields), approved for glioblastoma (GBM), affect the BBB’s integrity and permeability. Here, we treated murine microvascular cerebellar endothelial cells (cerebEND) with 100–300 kHz TTFields for up to 72 h and analyzed the expression of barrier proteins by immunofluorescence staining and Western blot. In vivo, compounds normally unable to cross the BBB were traced in healthy rat brain following TTFields administration at 100 kHz. The effects were analyzed via MRI and immunohistochemical staining of tight-junction proteins. Furthermore, GBM tumor-bearing rats were treated with paclitaxel (PTX), a chemotherapeutic normally restricted by the BBB combined with TTFields at 100 kHz. The tumor volume was reduced with TTFields plus PTX, relative to either treatment alone. In vitro, we demonstrate that TTFields transiently disrupted BBB function at 100 kHz through a Rho kinase-mediated tight junction claudin-5 phosphorylation pathway. Altogether, if translated into clinical use, TTFields could represent a novel CNS drug delivery strategy.
In a recent study, we showed in an in vitro murine cerebellar microvascular endothelial cell (cerebEND) model as well as in vivo in rats that Tumor-Treating Fields (TTFields) reversibly open the blood–brain barrier (BBB). This process is facilitated by delocalizing tight junction proteins such as claudin-5 from the membrane to the cytoplasm. In investigating the possibility that the same effects could be observed in human-derived cells, a 3D co-culture model of the BBB was established consisting of primary microvascular brain endothelial cells (HBMVEC) and immortalized pericytes, both of human origin. The TTFields at a frequency of 100 kHz administered for 72 h increased the permeability of our human-derived BBB model. The integrity of the BBB had already recovered 48 h post-TTFields, which is earlier than that observed in cerebEND. The data presented herein validate the previously observed effects of TTFields in murine models. Moreover, due to the fact that human cell-based in vitro models more closely resemble patient-derived entities, our findings are highly relevant for pre-clinical studies.
Ten thiosemicarbazone ligands obtained by condensation of pyridine-2-carbaldehyde, quinoline-2-carbaldehyde, 2-acetylpyridine, 2-acetylquinoline, or corresponding 2-pyridyl ketones with thiosemicarbazides RNHC(S)NHNH\(_{2}\) and R=CH\(_{3}\), C\(_{6}\)H\(_{5}\) were prepared in good yield. The reaction of [PdCl\(_{2}\)(cod)] with cod=1,5-cyclooctadiene or K\(_{2}\)[PtCl\(_{4}\)] resulted in a total of 17 Pd(II) and Pt(II) complexes isolated in excellent purity, as demonstrated by \(^{1}\)H, \(^{13}\)C, and, where applicable, \(^{195\)Pt NMR spectroscopy combined with CHNS analysis. The cytotoxicity of the title compounds was studied on four human glioblastoma cell lines (GaMG, U87, U138, and U343). The most active compound, with a Pd(II) metal centre, a 2-quinolinyl ring, and methyl groups on both the proximal C and distal N atoms exhibited an EC\(_{50}\) value of 2.1 μM on the GaMG cell lines, thus being slightly more active than cisplatin (EC\(_{50}\) 3.4 μM) and significantly more potent than temozolomide (EC\(_{50}\) 67.1 μM). Surprisingly, the EC\(_{50}\) values were inversely correlated with the lipophilicity, as determined with the “shake-flask method”, and decreased with the length of the alkyl substituents (C\(_{1}\)>C\(_{8}\)>C\(_{10}\)). Correlation with the different structural motifs showed that for the most promising anticancer activity, a maximum of two aromatic rings (either quinolinyl or pyridyl plus phenyl) combined with one methyl group are favoured and the Pd(II) complexes are slightly more potent than their Pt(II) analogues.
Non-small cell lung cancer, ovarian cancer, and pancreatic cancer all present with high morbidity and mortality. Systemic chemotherapies have historically been the cornerstone of standard of care (SOC) regimens for many cancers, but are associated with systemic toxicity. Multimodal treatment combinations can help improve patient outcomes; however, implementation is limited by additive toxicities and potential drug–drug interactions. As such, there is a high unmet need to develop additional therapies to enhance the efficacy of SOC treatments without increasing toxicity. Tumor Treating Fields (TTFields) are electric fields that exert physical forces to disrupt cellular processes critical for cancer cell viability and tumor progression. The therapy is locoregional and is delivered noninvasively to the tumor site via a portable medical device that consists of field generator and arrays that are placed on the patient’s skin. As a noninvasive treatment modality, TTFields therapy-related adverse events mainly consist of localized skin reactions, which are manageable with effective acute and prophylactic treatments. TTFields selectively target cancer cells through a multi-mechanistic approach without affecting healthy cells and tissues. Therefore, the application of TTFields therapy concomitant with other cancer treatments may lead to enhanced efficacy, with low risk of further systemic toxicity. In this review, we explore TTFields therapy concomitant with taxanes in both preclinical and clinical settings. The summarized data suggest that TTFields therapy concomitant with taxanes may be beneficial in the treatment of certain cancers.